Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4, Open-label Test-retest Study to Assess the Reproducibility of Quantitative Measurements of Myocardial Uptake of AdreView (Iobenguane I 123 Injection)

NCT01936649 is registered in ClinicalTrials.gov with GE Healthcare as lead sponsor.

NCT NCT01936649
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01936649 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4, Open-label Test-retest Study to Assess the Reproducibility of Quantitative Measurements of Myocardial Uptake of AdreView (Iobenguane I 123 Injection)
Lead sponsor
GE Healthcare
Phase
Phase 4
Overall status
Completed
Start date
August 31, 2013
Completion date
February 28, 2014
Enrollment
63 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure (hf), ventricular dysfunction, left